Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in western Kenya
Journal of Infectious Diseases, Volume 196, No. 9, Year 2007
Notification
URL copied to clipboard!
Description
Background. Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women. HIV-infected (HIV+) women require more frequent doses of intermittent preventive therapy with SP than do HIV-uninfected (HIV-) women. We investigated whether this reflects their impaired immunity or an HIV-associated alteration in the disposition of SP. Methods. Seventeen pregnant HIV- women and 16 pregnant HIV+ women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine. Five HIV- and 6 HIV+ postpartum women returned 2-3 months after delivery for another dose. The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups. Results. HIV status did not affect the area under the curve (AUC0→∞) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although partum status did have a significant affect on sulfadoxine pharmacokinetics. Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P < .001), and the median AUC0→∞ was ∼40% lower (22,816 vs 40,106 mg/mL/h, P < .001). HIV status and partum status did not show any significant influence on pyrimethamine pharmacokinetics. Conclusion. Pregnancy significantly modifies the disposition of SP, whereas HIV status has little influence on pharmacokinetic parameters in pregnant women. © 2007 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Green, Michael D.
United States, Atlanta
Centers for Disease Control and Prevention
van Eijk, Anna Maria
Netherlands, Amsterdam
Universiteit Van Amsterdam
ter Kuile, Feiko O.
United Kingdom, Liverpool
Liverpool School of Tropical Medicine
Ayisi, John G.
Kenya, Nairobi
Kenya Medical Research Institute
Parise, Monica E.
United States, Atlanta
Centers for Disease Control and Prevention
Kager, Petrus A.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Nahlen, Bernard L.
United States, Washington, D.c.
United States Agency for International Development
Steketee, Richard W.
France, Ferney-voltaire
Path
Nettey, Henry I.
United States, Atlanta
Centers for Disease Control and Prevention
Statistics
Citations: 76
Authors: 9
Affiliations: 6
Identifiers
Doi:
10.1086/522632
ISSN:
00221899
Research Areas
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Locations
Kenya
Participants Gender
Female